Sorry, your browser is out of date. To view this page correctly, please install a modern browser (Microsoft Edge, Firefox or Google Chrome).
SAI - Detailed view
Please log in as a company employee using your Swiss-Rx-Login. For further information please see the FAQ.
Spevigo 450 mg/7,5 ml (60 mg/ml) , Konzentrat zur Herstellung einer Infusionslösung 2
Drug
Spevigo, Konzentrat zur Herstellung einer Infusionslösung
Generalisierte pustulöse Psoriasis
07.15.0. – immunosuppressants
HAM – Human medicine
KOINF – Concentrate for solution for infusion
BT – biological medicines
A – Dispensed once only on prescription by a physician or veterinarian (A)
B – limited
8/9/2023
8/9/2025
Dosage strength
Spevigo 450 mg/7,5 ml (60 mg/ml) , Konzentrat zur Herstellung einer Infusionslösung
Generalisierte pustulöse Psoriasis
01
B – limited
Package
No information made available
A/NR – Authorised / not referenced
2 vial(s)
001
B – limited
Declaration
Component
450 mg spesolimabum
natrii acetas trihydricus
acidum aceticum glaciale
386 mg saccharum
arginini hydrochloridum
polysorbatum 20
aqua ad iniectabile
6.8 mg natrium
acidum aceticum glaciale
386 mg saccharum
arginini hydrochloridum
polysorbatum 20
aqua ad iniectabile
6.8 mg natrium
Authorisation holder
7601001002630
Boehringer Ingelheim (Schweiz) GmbH
Hochbergerstrasse 60B
4057 Basel (BS)
Hochbergerstrasse 60B
4057 Basel (BS)
Date of revision of the text
9/1/2023
Please log in as a company employee using your Swiss-Rx-Login. For further information please see the FAQ.
Data source: Swissmedic, *authorisation holder, **Refdata foundation, ***FOPH.